Abstract
Introduction: Nonfunctioning pancreatic neuroendocrine tumor (NF-PanNET) ≤2 cm can be observed or resected. Surgery remains recommended for NF-PanNET >2 cm but its extent, enucleation (EN) versus formal resection, remains controversial. Methods: Multicentric retrospective cohort of sporadic NF-PanNET patients treated with EN. Short- and long-term outcomes were compared according to tumor size on imaging ≤2 cm versus >2 cm. Results: 131 patients underwent EN for NF-PanNET, including 103 (79.0%) ≤2 cm and 28 (21.0%) >2 cm (extremes, 4–55 mm). Patients’ characteristics were comparable, and tumor characteristics only differed in their diameter. Clavien III-IV complications were similar (18.4% vs. 17.9%, p = 1.00) with one death in NF-PanNET ≤2 cm. Grade B/C pancreatic fistula were comparable (16.5% vs. 10.7%, p = 0.850). In NF-PanNET >2 cm there were more pT2/3 stage tumors (85.7% vs. 21.4%, p < 0.001), similar rates of grade G2/3 tumors (25% vs. 16.5%, p = 0.408) with a median Ki67 of 2 (interquartile range: 1–3), and of lymphovascular and perineural invasions. Lymph node picking was done in 46 (35.1%) patients, with a higher median number of harvested lymph nodes in NF-PanNET >2 cm (4 vs. 3, p = 0.01). All were pN0. R0 resection rate (78.6% vs. 82.5%, respectively; p = 0.670) was equivalent. Five-year overall (100% vs. 99%, p = 0.602) and 10-year disease-free (96% vs. 92%, respectively; p = 0.532) survivals were comparable. Conclusions: EN for selected NF-PanNET >2 cm carries equivalent morbidity, overall and disease-free survivals compared to those observed with NF-PanNET ≤2 cm.
Journal Section:
Research Article
References
1.
Yao
JC
, Hassan
M
, Phan
A
, Dagohoy
C
, Leary
C
, Mares
JE
, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
. J Clin Oncol
. 2008
;26
(18
):3063
–72
. 2.
Ehehalt
F
, Saeger
HD
, Schmidt
CM
, Grützmann
R
. Neuroendocrine tumors of the pancreas
. Oncologist
. 2009
;14
(5
):456
–67
. 3.
Lawrence
B
, Gustafsson
BI
, Chan
A
, Svejda
B
, Kidd
M
, Modlin
IM
. The epidemiology of gastroenteropancreatic neuroendocrine tumors
. Endocrinol Metab Clin North Am
. 2011
;40
(1
):1
–vii
. 4.
Vaghaiwalla
T
, Keutgen
XM
. Surgical management of pancreatic neuroendocrine tumors
. Surg Oncol Clin N Am
. 2020
;29
(2
):243
–52
. 5.
Falconi
M
, Eriksson
B
, Kaltsas
G
, Bartsch
DK
, Capdevila
J
, Caplin
M
, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors
. Neuroendocrinology
. 2016
;103
(2
):153
–71
. 6.
Vagefi
PA
, Razo
O
, Deshpande
V
, McGrath
DJ
, Lauwers
GY
, Thayer
SP
, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005
. Arch Surg
. 2007
;142
(4
):347
–54
. 7.
Referenced with permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines®) for neuroendocrine tumors of the pancreas (Well-Differentiated grade 1/2) V1.2024© national comprehensive cancer Network
. Inc
. 2024
. All rights reserved. Accessed [Jul 1st, 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org.8.
Dong
DH
, Zhang
XF
, Lopez-Aguiar
AG
, Poultsides
G
, Makris
E
, Rocha
F
, et al. Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence
. HPB Oxf
. 2020
;22
(2
):215
–23
. 9.
Nießen
A
, Bechtiger
FA
, Hinz
U
, Lewosinska
M
, Billmann
F
, Hackert
T
, et al. Enucleation is a feasible procedure for well-differentiated pNEN-A matched pair analysis
. Cancers
. 2022
;14
(10
):2570
. 10.
Pitt
SC
, Pitt
HA
, Baker
MS
, Christians
K
, Touzios
JG
, Kiely
JM
, et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate
. J Gastrointest Surg
. 2009
;13
(9
):1692
–8
. 11.
Bolm
L
, Nebbia
M
, Wei
AC
, Zureikat
AH
, Fernández-Del Castillo
C
, Zheng
J
, et al. Long-term outcomes of parenchyma-sparing and oncologic resections in patients with nonfunctional pancreatic neuroendocrine tumors <3 cm in a large multicenter cohort
. Ann Surg
. 2022
;276
(3
):522
–31
. 12.
Chen
J
, Yang
Y
, Liu
Y
, Kan
H
. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation
. World J Surg Oncol
. 2021
;19
(1
):11
. 13.
Bassi
C
, Marchegiani
G
, Dervenis
C
, Sarr
M
, Abu Hilal
M
, Adham
M
, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years after
. Surgery
. 2017
;161
(3
):584
–91
. 14.
Dindo
D
, Demartines
N
, Clavien
PA
. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey
. Ann Surg
. 2004
;240
(2
):205
–13
. 15.
Royal College of Pathologists
. Standards and datasets for reporting cancers Dataset for histopathological reporting of neuroendocrine neoplasms of the gastroenteropancreatic tract
. Available from: https://www.acpgbi.org.uk/_userfiles/import/2019/05/Dataset-for-histopathological-reporting-of-neuroendocrine-neoplasms-of-the-gastroenteropancreatic-tract-For-Consultation-002.pdf (accessed May, 2019).16.
Amin
MB
, Greene
FL
, Edge
SB
, Compton
CC
, Gershenwald
JE
, Brookland
RK
, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging
. CA Cancer J Clin
. 2017
;67
(2
):93
–9
. 17.
Kanda
Y
. Investigation of the freely available easy-to-use software “EZR” for medical statistics
. Bone Marrow Transplant
. 2013
;48
(3
):452
–8
. 18.
Hüttner
FJ
, Koessler-Ebs
J
, Hackert
T
, Ulrich
A
, Büchler
MW
, Diener
MK
. Meta-analysis of surgical outcome after enucleation versus standard resection for pancreatic neoplasms
. Br J Surg
. 2015
;102
(9
):1026
–36
. 19.
Heidsma
CM
, Tsilimigras
DI
, van Dieren
S
, Rocha
F
, Abbott
DE
, Fields
R
, et al. Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors
. HPB Oxf
. 2021
;23
(3
):413
–21
. 20.
Inchauste
SM
, Lanier
BJ
, Libutti
SK
, Phan
GQ
, Nilubol
N
, Steinberg
SM
, et al. Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors
. World J Surg
. 2012
;36
(7
):1517
–26
. 21.
Strobel
O
, Cherrez
A
, Hinz
U
, Mayer
P
, Kaiser
J
, Fritz
S
, et al. Risk of pancreatic fistula after enucleation of pancreatic tumours
. Br J Surg
. 2015
;102
(10
):1258
–66
. 22.
Brient
C
, Regenet
N
, Sulpice
L
, Brunaud
L
, Mucci-Hennekine
S
, Carrère
N
, et al. Risk factors for postoperative pancreatic fistulization subsequent to enucleation
. J Gastrointest Surg
. 2012
;16
(10
):1883
–7
. 23.
Sauvanet
A
, Gaujoux
S
, Blanc
B
, Couvelard
A
, Dokmak
S
, Vullierme
MP
, et al. Parenchyma-sparing pancreatectomy for presumed noninvasive intraductal papillary mucinous neoplasms of the pancreas
. Ann Surg
. 2014
;260
(2
):364
–71
. 24.
Hwang
HK
, Song
KB
, Park
M
, Kwon
W
, Jang
JY
, Heo
JS
, et al. Minimally invasive versus open pancreatectomy for right-sided and left-sided G1/G2 nonfunctioning pancreatic neuroendocrine tumors: a multicenter matched analysis with an inverse probability of treatment-weighting method
. Ann Surg Oncol
. 2021
;28
(12
):7742
–58
. 25.
Partelli
S
, Gaujoux
S
, Boninsegna
L
, Cherif
R
, Crippa
S
, Couvelard
A
, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)
. JAMA Surg
. 2013
;148
(10
):932
–9
. 26.
Sallinen
VJ
, Le Large
TYS
, Tieftrunk
E
, Galeev
S
, Kovalenko
Z
, Haugvik
SP
, et al. Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors: a multi-institutional study
. HPB Oxf
. 2018
;20
(3
):251
–9
. 27.
Sanli
Y
, Garg
I
, Kandathil
A
, Kendi
T
, Zanetti
MJB
, Kuyumcu
S
, et al. Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET/CT
. AJR Am J Roentgenol
. 2018
;211
(2
):267
–77
. 28.
Heidsma
CM
, van Roessel
S
, van Dieren
S
, Engelsman
AF
, Strobel
O
, Buechler
MW
, et al. International validation of a nomogram to predict recurrence after resection of grade 1 and 2 nonfunctioning pancreatic neuroendocrine tumors
. Neuroendocrinology
. 2022
;112
(6
):571
–9
. 29.
Rebours
V
, Cordova
J
, Couvelard
A
, Fabre
M
, Palazzo
L
, Vullierme
MP
, et al. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics
. Dig Liver Dis
. 2015
;47
(11
):973
–7
. 30.
Zerbi
A
, Falconi
M
, Rindi
G
, Delle Fave
G
, Tomassetti
P
, Pasquali
C
, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases
. Am J Gastroenterol
. 2010
;105
(6
):1421
–9
. 31.
Perinel
J
, Nappo
G
, Zerbi
A
, Heidsma
CM
, Nieveen van Dijkum
EJM
, Han
HS
, et al. Sporadic nonfunctional pancreatic neuroendocrine tumors: risk of lymph node metastases and aggressiveness according to tumor size: a multicenter international study
. Surgery
. 2022
;172
(3
):975
–81
. 32.
Partelli
S
, Gaujoux
S
, Boninsegna
L
, Cherif
R
, Crippa
S
, Couvelard
A
, et al. Pattern and clinical predictors of lymph node involvement in nonfunctioning pancreatic neuroendocrine tumors (NF-PanNETs)
. JAMA Surg
. 2013
;148
(10
):932
–9
. 33.
Jilesen
AP
, van Eijck
CH
, Busch
OR
, van Gulik
TM
, Gouma
DJ
, van Dijkum
EJ
. Postoperative outcomes of enucleation and standard resections in patients with a pancreatic neuroendocrine tumor
. World J Surg
. 2016
;40
(3
):715
–28
. 34.
Genç
CG
, Jilesen
AP
, Partelli
S
, Falconi
M
, Muffatti
F
, van Kemenade
FJ
, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors
. Ann Surg
. 2018
;267
(6
):1148
–54
. 35.
Pulvirenti
A
, Javed
AA
, Landoni
L
, Jamieson
NB
, Chou
JF
, Miotto
M
, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors
. Ann Surg
. 2021
;274
(6
):1051
–7
. 36.
Zaidi
MY
, Lopez-Aguiar
AG
, Switchenko
JM
, Lipscomb
J
, Andreasi
V
, Partelli
S
, et al. A novel validated recurrence risk score to guide a pragmatic surveillance strategy after resection of pancreatic neuroendocrine tumors: an international study of 1006 patients
. Ann Surg
. 2019
;270
(3
):422
–33
. 37.
Giuliani
T
, De Pastena
M
, Paiella
S
, Marchegiani
G
, Landoni
L
, Festini
M
, et al. Pancreatic enucleation patients share the same quality of life as the general population at long-term follow-up: a propensity score-matched analysis
. Ann Surg
. 2023
;277
(3
):e609
–16
. 38.
De Bruijn
KM
, van Eijck
CH
. New-onset diabetes after distal pancreatectomy: a systematic review
. Ann Surg
. 2015
;261
(5
):854
–61
. 39.
Dai
M
, Xing
C
, Shi
N
, Wang
S
, Wu
G
, Liao
Q
, et al. Risk factors for new-onset diabetes mellitus after distal pancreatectomy
. BMJ Open Diabetes Res Care
. 2020
;8
(2
):e001778
. 40.
Crinò
SF
, Napoleon
B
, Facciorusso
A
, Lakhtakia
S
, Borbath
I
, Caillol
F
, et al. Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for treatment of pancreatic insulinoma
. Clin Gastroenterol Hepatol
. 2023
;21
(11
):2834
–43.e2
. 41.
Khoury
T
, Sbeit
W
, Napoléon
B
. Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: a critical review focusing on safety, efficacy and controversies
. World J Gastroenterol
. 2023
;29
(1
):157
–70
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
